drugset / Trial / NCT02749370

Study to Evaluate the Efficacy of Etanercept Treatment in Adults Who Failed Therapy With Apremilast

NCT02749370

Phase 4 Completed 80 enrolled Amgen
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy of etanercept in adults with moderate to severe plaque psoriasis who have failed therapy with apremilast (Otezla).

Timeline

Start
2016-05-18
Primary completion
2017-08-14
Completion
2017-12-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Etanercept Protein / enzyme biologic 50 mg Subcutaneous

Indications